Newsbenzinga
Corbus Pharmaceuticals Announces First Patient Dosed In Registrational TEMPO-1 Study Of CRB-701 In Oropharyngeal Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…